Compare Stocks › BAC vs MRNA

Bank of America Corporation (BAC) vs Moderna, Inc. (MRNA): Which Is the Better Buy in 2026?

As of 2026-11-01, BAC is undervalued at $50, with a DCF intrinsic value of $180 and a margin of safety of 72%. MRNA is overvalued at $222, with an intrinsic value of $67 and a margin of safety of -233%. Of the two, BAC has the wider margin of safety.

BAC
Bank of America Corporation
$50.01
VS
MRNA
Moderna, Inc.
$221.72

Rewards

BAC
  • ★Bank of America Corporation scores 100/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • ★PEG ratio of 0.91 suggests the stock is undervalued relative to its growth rate — paying less than 1x for each unit of earnings growth.
MRNA

    Risks

    BAC
    • ⚠Gross margin of 0.0% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • ⚠Altman Z-Score of 0.22 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.
    MRNA
    • ⚠ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • ⚠Gross margin of -66.0% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • ⚠Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.

    Key Valuation Metrics

    Learn more →
    BAC
    MRNA
    Valuation
    N/A
    Free Cash Flow
    $299.25M
    N/A
    FCF Yield
    0.34%
    11.94
    Trailing P/E
    N/A
    9.64
    Forward P/E
    -48.35
    Quality & Moat
    3.80%
    ROIC
    -122.02%
    10.73%
    ROE
    -39.00%
    0.00%
    Gross Margin
    -66.02%
    0.91
    PEG Ratio
    N/A
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    Net cash
    N/A
    Interest Coverage
    N/A
    N/A
    Net Debt / EBITDA
    N/A
    2.56%
    Dividend Yield
    0.00%
    BAC: 4Ties: 1MRNA: 1
    BACMRNA

    Historical Fundamentals

    Learn more →
    BAC

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    BAC
    $2.37
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $55.63B
    Δ Market Cap
    +$131.83B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    BAC
    72.2% Margin of Safety
    Price is 72.2% below estimated fair value
    Current Price: $50.01
    Fair Value: $180.08
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    MRNA
    233.0% Overvalued
    Price is 233.0% above estimated fair value
    Current Price: $221.72
    Fair Value: $66.58
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    BAC

    Requires positive FCF to compute implied growth rate.

    MRNA

    What growth rate is the market pricing in at $222?

    +45.3%
    Market-Implied FCF Growth Rate

    Market pricing in significantly higher growth than history — aggressive.

    Economic Moat Score

    Learn more →
    BAC
    100/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat driven primarily by revenue predictability. Reinvestment Efficiency is the area most vulnerable to competitive pressure.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    BAC
    -2.31
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    BAC
    Insiders 7.1%Institutions 71.9%Retail & Other 21.0%
    No. of Institutional Holders4,517
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    MRNA
    Insiders 7.4%Institutions 80.5%Retail & Other 12.1%
    No. of Institutional Holders1,223
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    BAC
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    BAC
    0
    Sells (3M)
    5
    Sells (12M)
    Total value (12M): $20.17M
    MENSAH BERNARD AMPONSAH
    Officer
    $4.41M
    @ $46.94 · 2026-03-12
    SCRIVENER THOMAS M
    Officer
    $2.49M
    @ $49.82 · 2026-03-05
    BRONSTEIN SHERI B
    Officer
    $2.99M
    @ $49.91 · 2026-03-05
    ATHANASIA DEAN C
    President
    $6.86M
    @ $50.21 · 2026-03-03
    BORTHWICK ALASTAIR M.
    Chief Financial Officer
    $3.42M
    @ $50.24 · 2026-02-27
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    MRNA
    4
    Sells (3M)
    12
    Sells (12M)
    Total value (12M): $63.50M
    HOGE STEPHEN
    President
    $11.69M
    @ $145.10 · 2026-09-15
    MOCK JAMES M
    Chief Financial Officer
    $4.69M
    @ $134.49 · 2026-09-10
    KLINGER SHANNON THYME
    Officer
    $485,766
    @ $139.95 · 2026-09-01
    BANCEL STEPHANE J
    Chief Executive Officer
    $28.72M
    @ $57.52 · 2026-08-05
    HOGE STEPHEN
    President
    $3.61M
    @ $67.60 · 2026-07-15
    HOGE STEPHEN
    President
    $2.74M
    @ $51.37 · 2026-06-15
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    BAC
    FearGreed
    😨Fear(39/100)

    "Market is pessimistic — investigate whether fears are temporary or structural"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    MRNA
    FearGreed
    😐Neutral(52/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    BAC
    ⚪Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Fear (39)
    MRNA
    ⚪Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (52)
    View BAC Full AnalysisView MRNA Full Analysis

    Frequently Asked Questions: BAC vs MRNA

    Is Bank of America Corporation or Moderna, Inc. more undervalued in 2026?▼

    Based on our discounted cash flow model, BAC trades at a 72.2% margin of safety (intrinsic value $180 vs. price $50), compared to MRNA's -233.0% margin of safety (intrinsic $67 vs. $222).

    Which stock has a wider economic moat, Bank of America Corporation or Moderna, Inc.?▼

    BAC scores 100/100 (Wide moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Bank of America Corporation in financial distress?▼

    BAC's Altman Z-Score of 0.2 places it in the Distress zone, signaling elevated bankruptcy risk. MRNA scores 2.5 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which stock has higher return on invested capital, Bank of America Corporation or Moderna, Inc.?▼

    BAC earns 3.8% ROIC versus MRNA's -122.0%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.